Remix Teams Up With Second Big Pharma With Roche Deal For RNA Technology

Remix Therapeutics has added a second large pharma player to its list of partners in just under two years, while the partner, Roche Holding AG, has expanded its presence in the growing field of RNA-based therapeutics. Remix also scored a new venture capital infusion that it will devote toward clinical development of its lead product candidate in solid tumor and hematological oncology.

The Cambridge, MA-based biotech announced the deal with the Swiss drug maker and the close of a $60m financing on 3 January. The Column Group led the financing, with existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital and Surveyor (a Citadel company) participating, along with new investors WTT Investment, Willett Advisors and others. Remix previously raised a $70m series B round in May 2022, which followed $81m it raised in late 2020